Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China

Clinica Chimica Acta

Volumn 438, Issue , 2015, Pages 388-395

  Korse, Catharina M ^a   Holdenrieder, Stefan ^b   Zhi, Xiu yi ^c   Zhang, Xiaotong ^d   Qiu, Ling ^d   Geistanger, Andrea ^e   Lisy, Marcus Rene ^e   Wehnl, Birgit ^e   van den Broek, Daan ^a   Escudero, José M ^f   Standop, Jens ^b   Hu, Mu ^c   Molina, Rafael ^f  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e ROCHE DIAGNOSTICS GMBH   (Germany)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

Differential diagnosis; Immunoassay; Progastrin releasing peptide; ProGRP; SCLC; Stability

Indexed keywords

PROGASTRIN RELEASING PEPTIDE; PEPTIDE FRAGMENT; PRO-GASTRIN-RELEASING PEPTIDE (31-98); RECOMBINANT PROTEIN; TUMOR MARKER;

ADULT; AGE; ARCHITECT ASSAY; AREA UNDER THE CURVE; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; CHINA; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ETHNICITY; EUROPE; FEMALE; GENDER; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; INTERMETHOD COMPARISON; LUNG CANCER; MALE; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PLASMA; PROGASTRIN RELEASING PEPTIDE IMMUNOASSAY; SENSITIVITY AND SPECIFICITY; SERUM; SMALL CELL LUNG CANCER; SMOKING; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CAUCASIAN; CLINICAL TRIAL; ETHNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; STANDARDS;

ADULT; AGED; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHINA; DIAGNOSIS, DIFFERENTIAL; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOASSAY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84908136030     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.09.015     Document Type: Article

References (42)

1. Hensing T., Chawla A., Batra R., Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol 2014, 799:85-117.
2. Pass H.I., Beer D.G., Joseph S., Massion P. Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. Thorac Surg Clin 2013, 23:211-224.
3. Rosell R., Bivona T.G., Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013, 382:720-731.
4. Moran C. Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol 2011, 178:1940-1948.
5. Kulesza P., Ramchandran K., Patel J.D. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol 2011, 136:228-238.
6. Nisman B., Biran H., Ramu N., Heching N., Barak V., Peretz T. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res 2009, 29:4827-4832.
7. Kalemkerian G.P., Akerley W., Bogner P., et al. Small cell lung cancer. J Natl Compr Canc Netw 2013, 11:78-98.
8. Zarogoulidis K., Zarogoulidis P., Darwiche K., et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 2013, 5:S389-S396.
9. Chan B.A., Coward J.I. Chemotherapy advances in small-cell lung cancer. J Thorac Dis 2013, 5:S565-S578.
10. Harmsma M., Schutte B., Ramaekers F.C. Serum markers in small cell lung cancer: opportunities for improvement. Biochim Biophys Acta 1836, 2013:255-272.
11. Molina R., Auge J.M., Filella X., et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 2005, 25:1773-1778.
12. Molina R., Holdenrieder S., Auge J.M., Schalhorn A., Hatz R., Stieber P. Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomark 2010, 6:163-178.
13. European Group on Tumour Markers Tumour markers in lung cancer: EGTM recommendations. Anticancer Res 1999, 19:2817-2819.
14. Slodkowska J., Zych J., Szturmowicz M., Demkow U., Rowinska-Zakrzewska E., Roszkowski-Sliz K. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study. Int J Biol Markers 2005, 20:217-226.
15. Miyake Y., Kodama T., Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994, 54:2136-2140.
16. Molina R., Augé J.M., Bosch X., et al. Usefulness of serum tumor markers, including progastrin-releasing peptide in patients with lung cancer: correlation with histology. Tumour Biol 2009, 30:121-129.
17. Molina R. ProGRP: a new biomarker for small cell lung cancer. Eur J Clin Med Oncol 2009, 1:25-32.
18. Nakahama H., Tanaka Y., Fujita Y., Fujii M., Sugita M. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Respirology 1998, 3:207-210.
19. Inaji H., Komoike Y., Motomura K., et al. Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma. Oncology 2000, 59:122-125.
20. Molina R., Augé J.M., Alicarte J., Filella X., Viñolas N., Ballesta A.M. Pro-gastrin-releasing peptide in patients with benign and malignant disease. Tumour Biol 2004, 25:56-61.
21. Molina R., Bosch X., Augé J.M., et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumour Biol 2012, 33:463-474.
22. Korse C.M., Taal B.G., Bonfrer J.M., Vincent A., van Velthuysen M.L., Baas P. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival. Ann Oncol 2011, 22:2625-2630.
23. Yoshimura T., Fujita K., Kinukawa H., et al. Development and analytical performance evaluation of an automated chemiluminescent immunoassay for pro-gastrin releasing peptide (ProGRP). Clin Chem Lab Med 2009, 47:1557-1563.
24. Yoshimura T., Fujita K., Kawakami S., et al. Stability of pro-gastrin-releasing peptide in serum versus plasma. Tumour Biol 2008, 29:224-230.
25. Kim H.R., Oh I.J., Shin M.G., et al. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer. J Korean Med Sci 2011, 26:625-630.
26. Nordlund M.S., Warren D.J., Laerdahl J.K., Paus E. Studies on multiple forms of proGRP in serum from small cell lung cancer patients. Tumour Biol 2009, 30:265-275.
27. World Health Organization Histological typing of lung tumors 1999, WHO, Springer Verlag, Geneva. 3rd ed.
28. Travis W.D., Brambilla E., Noguchi M., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
29. CLSI Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. CLSI document EP05-A2 2004, Clinical and Laboratory Standards Institute, Wayne, PA. 2nd ed.
30. Linnet K. Evaluation of regression procedures for methods comparison studies. Clin Chem 1993, 39:424-432.
31. Carpenter J., Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000, 19:1141-1164.
32. Hahn G.J., Meeker W.Q. Statistical Intervals: A Guide for Practitioners 1991, Wiley, New York.
33. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
34. Matsushita K., Mahmoodi B.K., Woodward M., et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012, 307:1941-1951.
35. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
36. Abbott ARCHITECT ProGRP package insert, 2009.
37. Fujirebio ProGRP package insert, 2011.
38. Biran H., Perelman M., Nisman B., et al. Circulating ProGRP and tissue thyroid transcription factor 1 (TTF1) in small-cell lung carcinoma (SCLC) limited versus extensive stages. J Clin Oncol 2014, 32(Suppl.):e18555. (Abst).
39. Ono A., Naito T., Ito I., et al. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Lung Cancer 2012, 76:439-444.
40. Yang H.J., Gu Y., Chen C., Xu C., Bao Y.X. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis. Clin Chem Lab Med 2011, 49:1039-1046.
41. Tang J.H., Zhang X.L., Zhang Z.H., et al. Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: a systematic review. Chin Med J (Engl) 2011, 124:1563-1568.
42. Holdenrieder S., von Pawel J., Dankelmann E., et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008, 14:7813-7821.